Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .


These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

Publications of the Division of Health Economics

Journals with external peer review


M. Schlander, W. van Harten, V. P. Retèl, P. D. Pham, J. M. Vancoppenolle, J. Ubels, O. S. López, C. Quirland, F. Maza, E. Aas, B. Crusius, A. Escobedo, N. Franzen, J. Fuentes-Cid, D. Hernandez, K. Hernandez-Villafuerte, I. Kirac, A. Paty, T. Philip , S. Smeland, R. Sullivan, E. Vanni, S. Varga, T. Vermeulin, R. D. Eckford:
The socioeconomic impact of cancer on patients and their relatives: Organisation of European Cancer Institutes task force consensus recommendations on conceptual framework, taxonomy, and research directions.
The Lancet Oncology, 2024: 25(4) e152-e163.
DOI: 10.1016/S1470-2045(23)00636-8.

M. T. Muchadeyi, K. Hernandez-Villafuerte, G. L. Di Tanna, R. D. Eckford, Y. Feng, M. Meregaglia, T. Peasgood, S. Petrou, J. Ubels, M. Schlander:
Quality Appraisal in Systematic Literature Reviews of Studies Eliciting Health State Utility Values: Conceptual Considerations.
Pharmacoeconomics: published online 29 March 2024.
DOI: 10.1007/s40273-024-01365-z. 

M. W. Lwin, C.-Y. Cheng, S. Calderazzo, C. Schramm, M. Schlande:
Would initiating colorectal cancer screening from age of 45 be cost-effective in Germany? An individual-level simulation analysis.
Frontiers in Public Health, published online 2024 Feb 21: Article12:1307427.
DOI: 10.3389/fpubh.2024.1307427.


P.D. Pham, M. Schlander, R. Eckford, K. Hernandez-Villafuerte, J. Ubels
Developing a Conceptual Framework for Socioeconomic Impact Research in European Cancer Patients: A 'Best-Fit' Framework Synthesis
The Patient - Patient-Centered Outcomes Research, 2023:16, 515-536.
DOI: 10.1007/s40271-023-00632-z.

R. Schaefer, D. Hernandez, T. Baernighausen, P. Kolominsky-Rabas, M. Schlander:
The HTA-informed Decision-Making by GBA/IQWiG in Germany and NICE in England: The Role of Budget Impact.
Value Health, 2023: 26(7):1032-1044
DOI: 10.1016/j.jval.2023.02.018.

D. Hernandez, C.-Y. Cheng, K. Hernandez-Villafuerte, M. Schlander:
Survival and comorbidities in lung cancer patients: evidence from administrative claims data in Germany
Oncology Research, 2022: 30(4),173-185.
DOI: 10.32604/or.2022.027262.

C.-Y. Cheng, S. Calderazzo, C. Schramm, M. Schlander
Modeling the natural history and screening effects for colorectal cancer using both adenoma and serrated neoplasia pathways: the development, calibration, and validation of a discrete event simulation model.
MDM Policy & Practice, 2023: 8(1), published 21 Jan 2023.
DOI: 10.1177/23814683221145701.

S. A. Khan
, K. Hernandez-Villafuerte, D. Hernandez, M. Schlander:
Estimation of the stage-wise costs of breast cancer in Germany using a modeling approach.
Frontiers in Public Health, 2023: 10, published 6 Jan 2023: Article 10:946544
DOI: 10.3389/fpubh.2022.946544.

J. Schneider, D. Hernandez, CAESAR study group, M. Schlander, V. Arndt:
Out-of-pocket payments and loss of income among long-term breast cancer survivors in Germany: A multi-regional population-based study.
Journal of Cancer Survivorship, 2023: 17 1639-1659.
DOI: 10.1007/s11764-022-01293-x.

D. HernandezF. WagnerK. Hernandez-VillafuerteM. Schlander:
Economic burden of pancreatic cancer in Europe: a literature review.
Journal of Gastrointestinal Cancer, 2023: 54 391-407.
DOI: 10.1007/s12029-022-00821-3.


M. T. Muchadeyi, K. Hernandez-Villafuerte, M. Schlander:
Quality appraisal for systematic literature reviews of health state utility values: a descriptive analysis.
BMC Medical Research Methodology, 2022: 22 (1) 303.
DOI: 10.1186/s12874-022-01784-6.

V. Arndt, D. Hernandez, M. Schlander:
Einkommenseinbußen nach Krebs – Ergebnisse aus Deutschland.
Onkologie, 2022: 28 951-956.
DOI: 10.1007/s00761-022-01243-3.

M. Brougham, M. Schlander, H. Telser, S. Bakshi, O. Sola-Morales:
Use of the incremental cost effectiveness ratio for decision-making policies - what's the problem? A perspective paper.
Expert Review of Pharmacoeconomics & Outcomes Research, 2022: 22 (6) 913-918.
DOI: 10.1080/14737167.2022.2064847.

J. Ubels, K. Hernandez-Villafuerte, M. Schlander:
The value of freedom: a review of the current developments and conceptual issues in the measurement of capability.
Journal of Human Development and Capabilities, 2022: 23 (3) 327-353.
DOI: 10.1080/19452829.2022.2053506.

J. W. März, A. Molnar, S. Holm, M. Schlander:
The ethics of COVID-19 vaccine allocation: Don't forget the trade-offs!
Public Health Ethics, 2022: 15 (1) 41-50.
DOI: 10.1093/phe/phac001.

D. Moro, M. Schlander, H. Telser, O. Sola-Morales, M. D. Clark, A. Olaye, C. Camp, M. Jain, T. Butt, S. Bakshi:
Evaluating discrete choice experiment willingness to pay [DCE-WTP] analysis, and relative social willingness to pay [RS-WTP] analysis in a health technology assessment of a treatment for an ultra-rare childhood disease [CLN2].
Expert Review or Pharmacoeconomics & Outcomes Research, 2022: 22 (4) 581-598.
DOI: 10.1080/14737167.2022.2014324.

R. D. Eckford, A. Gaisser, V. Arndt, M. Baumann, E. Kludt, K. Mehlis, J. Ubels, E. C. Winkler, S. Weg-Remers, M. Schlander:
The COVID-19 pandemic and cancer patients in Germany: impact on treatment, follow-up and psychological burden.
Frontiers in Public Health, published online 2022 Feb 9: Article 788598.
DOI: 10.3389/fpubh.2021.788598.

A. Gaisser, R. D. Eckford, V. Arndt, D. Doege, E. Kludt, J. Ubels, M. Schlander, S. Weg-Remers:
Fast zwei Jahre Coronapandemie aus der Perspektive von Krebsbetroffenen [Nearly two years of the coronavirus pandemic from the perspective of people affected by cancer].
Der Onkologe, 2022: 28 (3) 248-252.
DOI: 10.1007/s00761-022-01096-w.

M. S. Y. Thong, D. Doege, L. Weißer, L. Koch-Gallenkamp, H. Bertram, A. Eberle, B. Holleczek, A. Nennecke, A. Waldmann, S. R. Zeissig, R. Pritzkuleit, M. Schlander, H. Brenner, V. Arndt:
Health and life insurance-related problems in very long-term cancer survivors in Germany: a population-based study.
Journal of Cancer Research and Clinical Oncology, 2022: 148 (1) 155-162.
DOI: 10.1007/s00432-021-03825-x.


J. W. März, S. Holm, M. Schlander:
Resource allocation in the Covid-19 health crisis: are Covid-19 preventive measures consistent with the Rule of Rescue?
Medicine, Health Care and Philosophy, 2021: 24 (4) 487-492.
DOI: 10.1007/s11019-021-10045-0.

R. Schaefer, D. Hernandez, L Selberg, M. Schlander:
Health technology assessment (HTA) in England, France and Germany: what do matched drug pairs tell us about recommendations by national HTA agencies?
Journal of Comparative Effectiveness Research, 2021: 10 (16) 1187-1195.
DOI: 10.2217/cer-2021-0047.

M. SchlanderK. Hernandez-VillafuerteC. -Y. Cheng, J. Mestre-Ferrandiz, M. Baumann:
How much does it cost to research and develop a new drug? A systematic review and assessment.
Pharmacoeconomics, 2021: 39 (11) 1243-1269.
DOI: 10.1007/s40273-021-01065-y.

C. -Y. Cheng, T. Datzmann, D. Hernandez, J. Schmitt, M. Schlander:
Do certified cancer centers provide more cost-effective care? A health economic analysis of colon cancer care in Germany using administrative data.
International Journal of Cancer, 2021: 149 (10) 1744-1754.
DOI: 10.1002/ijc.33728.

A. Deibel, L. Deng, C. -Y. ChengM. SchlanderT. Ran, B. Lang, N. Krupka, N. Beerenwinkel, G. Rogler, R. Wiest, A. Sonnenberg, J. Poleszczuk, B. Misselwitz:
Evaluating key characteristics of ideal colorectal cancer screening modalities: the microsimulation approach.
Gastrointestinal Endoscopy, 2021: 94 (2) 379-390.e7.

D. Hernandez, M. Schlander:
Income loss after a cancer diagnosis in Germany: An analysis based upon the socio-economic panel survey.
Cancer Medicine, 2021: 10 (11) 3726-3740.
DOI: 10.1002/cam4.3913.

S. A. Khan, K. V. Hernandez-Villafuerte, M. T. Muchadeyi, M. Schlander:
Cost-effectiveness of risk-based breast cancer screening: A systematic review.
International Journal of Cancer, 2021: 149 (4) 790-810.
DOI: 10.1002/ijc.33593.


T. Ran, S. B. Eichmüller, P. Schmidt, M. Schlander:
Cost of decentralized CAR T cell production in an academic non-profit setting.
International Journal of Cancer, 2020: 147 (12) 3438-3445.
DOI: 10.1002/ijc.33156.

M. -J. Linton, P. M. Mitchell, H. Al-Janabi, M. Schlander, J. Richardson, A. Iezzi, J. Ubels, J. Coast:
Comparing the German translation of the ICECAP-A capability wellbeing measure to the original English version: psychometric properties across healthy samples and seven health condition groups.
Applied Research in Quality of Life, 2020: 15 (3) 651-673.
DOI: 10.1007/s11482-018-9681-5.

J. M. Heard, C. Vrinten, M. Schlander, C. M. Bellettato, C. van Lingen, M. Scarpa; MetabERN collaboration group:
Availability, accessibility and delivery to patients of the 28 orphan medicines approved by the European Medicine Agency for hereditary metabolic diseases in the MetabERN network.
Orphanet Journal of Rare Diseases, 2020: 15 (1) 1-10.
DOI: 10.1186/s13023-019-1280-5.



T. Ran, C. -Y. Cheng, B. Misselwitz, H. Brenner, J. Ubels, M. Schlander:
Cost–effectiveness of colorectal cancer screening strategies: A systematic review.
Clinical Gastroenterology and Hepatology, 2019: 17 (10) 1969-1981.
DOI: 10.1016/j.cgh.2019.01.014.

M. Wagner, D. Samaha, R. Casciano, M. Brougham, P. Abrishami, C. Petrie, B. Avouac, L. Mantovani, A. Sarría-Santamera, P. Kind, M. Schlander:
Moving towards accountability for reasonableness: A systematic exploration of the features of legitimate healthcare coverage decision-making processes using rare diseases and regenerative therapies as a case study.
International Journal of Health Policy and Management, 2019: 8 (7) 424-443.
DOI: 10.15171/ijhpm.2019.24.

R. Schaefer, M. Schlander:
Is the National Institute for Health and Care Excellence (NICE) in England more ´innovation-friendly´ than the Federal Joint Committee (GBA) in Germany?
Expert Review of Pharmacoeconomics & Outcomes Research, 2019: 19 (4) 453-462.
DOI: 10.1080/14737167.2019.1559732.

J. J. Caro, J. E. Brazier, J. Karnon, P. Kolominsky-Rabas, A. J. McGuire, E. Nord, M. Schlander:
Determining value in Health Technology Assessment: Stay the course or tack away?
PharmacoEconomics, 2019: 37 (3) 293-299.
DOI: 10.1007/s40273-018-0742-2.

J. Richardson, M. Schlander:
Health Technology Assessment (HTA) and economic evaluation: Efficiency or fairness first.
Journal of Market Access & Health Policy, 2019: 7 (1) 1557981.
DOI: 10.1080/20016689.2018.1557981.

V. Jantzer, M. Schlander, J. Haffner, P. Parzer, S. Trick, F. Resch, M. Kaess:
The cost incurred by victims of bullying from a societal perspective: Estimates based on a German online survey of adolescents.
European Child and Adolescent Psychiatry, 2019: 28 (4) 585-594.
DOI: 10.1007/s00787-018-1224-y.


M. Schlander, C. -Y. Cheng, T. Ran:
The health economics of cancer screening in Germany: Which population-based interventions are cost-effective? [Gesundheitsökonomie der Krebsfrüherkennung in Deutschland: Welche Interventionen sind kosteneffektiv bei bevölkerungsweiter Umsetzung?]
Bundesgesundheitsblatt, 2018 61 (12) 1559-1568.
DOI: 10.1007/s00103-018-2839-3.

J. Espin, M. Schlander, B. Godman, P. Anderson, J. Mestre-Ferrandiz, I. Borget, A. Hutchings, S. Flostrand, A. Paranby, C. Jommi:
Projecting pharmaceutical expenditure in EU5 to 2021: Adjusting for the impact of discounts and rebates.
Applied Health Economics and Health Policy, 2018 16 (6) 803-817.
DOI: 10.1007/s40258-018-0419-1.

M. Schlander, C. M. Dintsios, A. Gandjour:
Budgetary Impact and Cost Drivers of Drugs for Rare and Ultrarare Diseases.
Value in Health, 2018: 21 (5): 525-531.
DOI: 10.1016/j.jval.2017.10.015.

K. Hernandez-Villafuerte, A. Fischer, N. R. Latimer:
Challenges and methodologies in using progression free survival as a surrogate for overall survival in oncology.
International Journal of Technology Assessment in Health Care, (2018) 34(3) 300-316.
DOI: 10.1017/S0266462318000338.


G. Steigner, C. Doarn, M. Schütte, D. Matusiewicz, C. Thielscher:
Health applications for corporate health management.
Telemedicine and E-Health, 2017: 23 (5) 448-452.
DOI: 10.1089/tmj.2016.0162.

L. Annemans, S. Aymé, Y. Le Cam, K. Facey, P. Gunther, E. Nicod, M. Reni, J. -L. Roux, M. Schlander, D. Taylor, C. Tomino, J, Torrent-Farnell, S. Upadhyaya, A. Hutchings, L. Le Dez:
Recommendations from the European working group for value assessment and funding processes in rare diseases.
Orphanet Journal of Rare Diseases, 2017: 12 (1) 50.
DOI: 10.1186/s13023-017-0601-9.

K. Hernandez-Villafuerte, J. Sussex, E. Robin, S. Guthrie, S. Wooding:
Economies of scale and scope in publicly funded biomedical and health research: Evidence from the literature.
Health Research Policy and Systems, (2017) 15 (1) 3.
DOI: 10.1186/s12961-016-0167-3.

Non-refereed publications


D. Hernandez, S.A. Khan, M. Schlander
Krankheitslast von Brustkrebs in Deutschland: Epidemiologie und Kosten
Forum, 2023: published 20 June 2023.
DOI: 10.1007/s12312-023-01216-6

M. Schlander:
High-quality healthcare pays off (English version)
Aufwendige Gesundheitsversorgung zahlt sich aus (German version)
Gesundheitsindustrie BW, 11.1.2023 online.



D. Hernandez, T. Ran, K. Hernandez-Villafuerte, M. Schlander:
Krankheitslast von Darmkrebs in Deutschland: Epidemiologie und Kosten.
Forum, 2022: published 24 Nov 2022.
DOI: 10.1007/s12312-022-01154-9.

M. Schlander
, J. Richardson:
QALYs in health resource usage decisions.
Health Affairs, 2022: 41 (4) 609-610.
DOI: 10.1377/hlthaff.2021.01926.

D. Hernandez, P. Giri, A. von Both, M. Schlander:
Krankheitslast von Lungenkrebs in Deutschland: Epidemiologie und Kosten [Lung cancer disease burden in Germany: epidemiology and costs].
Forum, 2022: 37, 387-404.
DOI: 10.1007/s12312-022-01123-2.

D. Hernandez
, A. von Both, M. Schlander:
Krankheitslast von Prostatakrebs in Deutschland: Epidemiologie und Kosten [Disease burden of prostate cancer in Germany: epidemiology and costs].
Forum, 2022: 37 227-234.
DOI: 10.1007/s12312-022-01075-7.

D. Hernandez, K. Hernandez-Villafuerte, M. Schlander:
Die Messung der Kosten von Krebserkrankungen in Deutschland. Teil 2 – Wirtschaftliche Belastung [Determining the cost of cancer in Germany. Part 2—economic burden].
Forum, 2022: 37 42-48.
DOI: 10.1007/s12312-021-01026-8.

A. Gaisser, R.D. Eckford, V. Arndt, D. Doege, E. Kluddt, J. Ubels, M. Schlander, S. Weg-Remers:
Fast zwei Jahre Coronapandemie aus der Perspektive von Krebsbetroffenen [Nearly two years of the coronavirus pandemic from the perspective of people affected by cancer].
Forum, 2022: 37 216–220.
DOI: 10.1007/s12312-022-01092-6.


D. Hernandez, K. Hernandez-Villafuerte, M. Schlander:
Die Messung der Kosten von Krebserkrankungen in Deutschland: Teil 1 – Epiemiologie und Krankheitslast [Determining the cost of cancer in Germany. Part 1 – epidemiology and disease burden].
Forum, 2021: 36 406-410.
DOI: 10.1007/s12312-021-00988-z.

J. W. MärzM. Schlander:
Not kennt kein Gebot? Die Rule of Rescue als Leitprinzip in der Covid-19-Pandemie.
AMOS International, 2021: 15 (3): 39-44.

J. Ubels:
Saving money, saving lives: Health economics as a guide to cost-effective decision making.
International Journal of Cardiology, 2021: (339) 130-131.
DOI: 10.1016/j.ijcard.2021.06.053.

J. Ubels:
The assessment of value in health economics: utility and capability.
Defining the Value of Medical Interventions: Normative and Empirical Challenges (E-Book), 2021: 69-81.
ISBN (Print): 978-3-17-038176-6.

M. Schlander:
HTA agencies need evidence-informed deliberative processes. Comment on "Use of evidence-informed deliberative processes by health technology assessment agencies around the globe.
International Journal of Health Policy Management, 2021: 10 (3) 158-161.
DOI: 10.34172/ijhpm.2020.22.

T. Ran, S. B. Eichmüller, P. Schmidt, M. Schlander:
Reply to: Comments on "Cost of decentralized CAR T cell production in an academic non-profit setting"
International Journal of Cancer, 2021: 148 (2) 516-517.
DOI: 10.1002/ijc.33253.


M. Schlander:
PRO ("patient-reported outcomes") und Lebensqualität in der Onkologie [Patient-reported outcomes (PRO) and quality of life in oncology].
Forum, 2020: (35) 382-390.
DOI: 10.1007/s12312-020-00841-9. 

M. Schlander:
HTA agencies need evidence-informed deliberative processes. Comment on "Use of evidence-informed deliberative processes by health technology assessment agencies around the globe.
International Journal of Health Policy Management (2020): 10 (3) 158-161.
DOI: 10.34172/ijhpm.2020.22

M. Schlander:
Allen Patienten gerecht werden. Gedanken eines Gesundheitsökonomen zur COVID-19-Krise.
Frankfurter Allgemeine Zeitung FAZ, 2020 May 29: (24) 20.


C. Thielscher,B. Krol, S. Heinemann, M. Schlander:
Ethical decomposition as a new method to analyse moral dilemma.
INFORMATIK 2019, Hrsg: David, Geihs, Lange, Stumme.
Lecture Notes in Informatics (LNI), Gesellschaft für Informatik, 2019. Bonn.
DOI: 10.18420/inf2019_07

M. Schlander
The economic evaluation of health care interventions: Opportunities for cooperation between the Division of Health Economics at DKFZ & clinical researchers (at U of Heidelberg, NCT, DKTK).
Heidelberg, 2019, April 17.



K. Hernandez-Villafuerte, B. Zamora, Y. Feng, D. Parkin, N. Devlin, A. Towse:
Exploring variations in the opportunity cost cost-effectiveness threshold by clinical area: Results from a feasibility study in England.
Office of Health Economics, 2018: OHE Research Paper 19/3.

M. Schlander, K. Hernandez-Villafuerte, C. Thielscher:
Cost of cancer in Germany [Kosten der Onkologie in Deutschland].
Forum, 2018: 33 (5) 330-337.
DOI: 10.1007/s12312-018-0481-5

K. Hernandez-Villafuerte, B. Zamora, A. Towse:
Issues surrounding the estimation of the opportunity cost of adopting a new health care technology: Areas for Further Research.
Office of Health Economics, 2018: OHE Research Paper 18/7.

A. Towse, K. Hernandez-Villafuerte, B. Shaw:
A critique of the paper “The estimated costs of production and potential prices for the World Health Organization Essential Medicines List”.
Office of Health Economics, 2018: OHE Consulting Report.

M. Schlander:
Was ist uns die Krebsversorgung wert?
360° Onkologie Krebs und Politik, 2018: 2 (5) 4.

M. Schlander:
Das Schreckgespenst der Kostenexplosion ist nicht gut begründet.
Frankfurter Allgemeine Zeitung, 2018 Apr13: V2.

H. Telser, B. Fischer, M. Schlander:
Knappe Ressourcen und unbegrenzte Wünsche.
Im Dialog - CSS Journal 1, 2018: 4-6.

M. Schlander, B. Fischer, H.Telser:
Mithilfe der Wissenschaft die Kosten bremsen.
Im Dialog - CSS Journal 1, 2018: 8-9.


T. Penzel, I. Flindell, R. Höger, U. Krämer, M. Schlander, J. Vogt, H.-E. Wichmann:
Evaluierung der Forschung zur Wirkung von Fluglärm auf den Menschen.
Interdisziplinäres Schlafzentrum Charité, Universitätsmedizin Berlin, 2017.

C. Thielscher:
Was kann die Gesundheitswirtschaft von der Medizin lernen?
D. Matusiewicz, M. Muhrer-Schwaiger (eds.):
Neuvermessung der Gesundheitswirtschaft, Springer, 2017: 253-268.
DOI: 10.1007/978-3-658-12519-6_23

M. Schlander, O. Schwarz, G.-E. Trott:
Unanswered questions: ADHD in Germany: trends in diagnosis and pharmacotherapy [ADHS in Deutschland: Trends in Diagnose und medikamentöser Therapie].
Deutsches Ärzteblatt International 2017: 114 (25) 428-429.
DOI: 10.3238/arztebl.2017.0428a

M. Schlander:
Woran bemisst sich Effizienz im Gesundheitswesen? Zur Klärung fachwissenschaftlicher Begriffe und Kriterien.
Amos International, 2017: 11 (1) 22-31.

M. Schlander:
Gescheiterte Börsenfusion – oder "Whatever it takes".
Frankfurter Allgemeine Zeitung (FAZ), 2017 Apr 11: 6.

to top
powered by webEdition CMS